Catalyst Pharmaceuticals will lose patent protection for FIRDAPSE in February 2035, triggering an expected 70-80% revenue decline within two to three years as generic competitors enter the market.
FIRDAPSE generated approximately $254 million in revenue for Catalyst in 2023, representing the bulk of the company's total sales. The drug treats Lambert-Eaton myasthenic syndrome, a rare neuromuscular disorder affecting roughly 3,000 patients in the United States.
Generic erosion typically accelerates rapidly once exclusivity ends. Industry data shows branded rare disease drugs lose 60-90% market share within 24 months of generic entry, as payers and pharmacy benefit managers shift patients to lower-cost alternatives.
Catalyst acquired FIRDAPSE rights in 2012 and launched the product in 2019 after securing FDA approval. The company priced the treatment at approximately $375,000 annually, drawing scrutiny from lawmakers and patient advocates given that a similar formulation had been available through compassionate use programs at no cost.
The 2035 patent expiration gives Catalyst an 11-year runway to diversify revenue sources or develop patent life-cycle extensions. Companies facing similar cliffs typically pursue new formulations, additional indications, or acquisition strategies to offset generic impact.
Catalyst currently trades at 8.5 times forward earnings, below the biotech sector average of 15-20 times, suggesting investors have partially priced in the patent risk. The company holds approximately $150 million in cash with minimal debt.
Management has expanded the FIRDAPSE franchise to include myasthenia gravis, though this indication faces more competition from established treatments like pyridostigmine. The company also markets Fycompa for epilepsy under license from Eisai.
Generic manufacturers typically file abbreviated new drug applications 3-4 years before patent expiration. Catalyst could face paragraph IV challenges earlier if generic firms identify patent vulnerabilities or argue the patents are invalid.
The stock declined 3% following the disclosure of the 2035 expiration date in recent regulatory filings. Analysts project Catalyst needs to generate $400-500 million in new revenue by 2038 to maintain current valuation levels after generic substitution reduces FIRDAPSE sales to $50-75 million annually.